biostudies-literatureUnknown11(3)Piccirillo GAs recently reported, elevated fasting glucose plasma level constitutes a risk factor for 30-day total mortality in acutely decompensated chronic heart failure (CHF). Aim of this study was to evaluate the 30-day mortality risk in decompensated CHF patients by fasting glucose plasma level and some repolarization ECG markers.<h4>Method</h4>A total of 164 decompensated CHF patients (M/F: 94/71; mean age, 83 ± 10 years) were studied; Tend (Te), QT interval (QT) and 5 min of ECG recordings were obtained, studying mean, SD and normalized index of the abovementioned ECG intervals. These repolarization variables and fasting glucose were analyzed to assess the 30-day mortality risk among these patients.<h4>Results</h4>Thirty-day mortality rate was 21%, deceased subjects showed a significant increase in N terminal-pro-brain natriuretic peptide (<i>P</i> < 0.001), higher sensitivity cardiac troponin, fasting glucose, creatinine clearance, QTSD, QTVN, Te mean, TeSD and TeVN than the survivals. Multivariable regression analysis reported that fasting glucose (hazard ratio, 1.59; 95% confidence interval, 1.09-2.10; <i>P</i> < 0.01), Te mean (hazard ratio, 1.03; 95% confidence interval, 1.01-1.05; <i>P</i> < 0.01) and QTSD (hazard ratio, 1.17; 95% confidence interval, 1.01-1.36; <i>P</i> < 0.05) were significantly related to higher mortality risk, whereas only fasting glucose (hazard ratio, 1.84; 95% confidence interval, 1.12-3.02; <i>P</i> < 0.05) and Te mean (hazard ratio, 1.07; 95% confidence interval, 1.02-1.11; <i>P</i> < 0.01) were associated to cardiovascular mortality.<h4>Conclusion</h4>Data suggest that two simple, inexpensive, noninvasive markers, as fasting glucose and Te, were capable to stratify the short-term total and cardiovascular mortality risk in acutely decompensated CHF.Cardiovascular endocrinology & metabolisme0264https://www.ebi.ac.uk/biostudies/studies/S-EPMC9155175biostudies-literatureGlucose dysregulation and repolarization variability markers are short-term mortality predictors in decompensated heart failure.PMC9155175Carnovale MCorrao AMoscucci FMagri DDi Diego ISciomer SLospinuso IPiccirillo GRossi PfalseGlucose dysregulation and repolarization variability markers are short-term mortality predictors in decompensated heart failure.As recently reported, elevated fasting glucose plasma level constitutes a risk factor for 30-day total mortality in acutely decompensated chronic heart failure (CHF). Aim of this study was to evaluate the 30-day mortality risk in decompensated CHF patients by fasting glucose plasma level and some repolarization ECG markers.<h4>Method</h4>A total of 164 decompensated CHF patients (M/F: 94/71; mean age, 83 ± 10 years) were studied; Tend (Te), QT interval (QT) and 5 min of ECG recordings were obtained, studying mean, SD and normalized index of the abovementioned ECG intervals. These repolarization variables and fasting glucose were analyzed to assess the 30-day mortality risk among these patients.<h4>Results</h4>Thirty-day mortality rate was 21%, deceased subjects showed a significant increase in N terminal-pro-brain natriuretic peptide (<i>P</i> < 0.001), higher sensitivity cardiac troponin, fasting glucose, creatinine clearance, QTSD, QTVN, Te mean, TeSD and TeVN than the survivals. Multivariable regression analysis reported that fasting glucose (hazard ratio, 1.59; 95% confidence interval, 1.09-2.10; <i>P</i> < 0.01), Te mean (hazard ratio, 1.03; 95% confidence interval, 1.01-1.05; <i>P</i> < 0.01) and QTSD (hazard ratio, 1.17; 95% confidence interval, 1.01-1.36; <i>P</i> < 0.05) were significantly related to higher mortality risk, whereas only fasting glucose (hazard ratio, 1.84; 95% confidence interval, 1.12-3.02; <i>P</i> < 0.05) and Te mean (hazard ratio, 1.07; 95% confidence interval, 1.02-1.11; <i>P</i> < 0.01) were associated to cardiovascular mortality.<h4>Conclusion</h4>Data suggest that two simple, inexpensive, noninvasive markers, as fasting glucose and Te, were capable to stratify the short-term total and cardiovascular mortality risk in acutely decompensated CHF.2022-01-01T00:00:00Z2022 Sep2025-04-25T16:52:48.338Z2025-02-19T04:04:49.992ZS-EPMC91551753566445110.1097/XCE.0000000000000264